This page provides a list of selected clinical guidelines related to tuberculosis (TB) topics. Guidelines are sorted by topics: testing and diagnosis, treatment, drug resistance, infection control, and specific populations.
This Joint Panel guideline updates the 2016 and 2019 TBtreatmentguidelines (6, 7) in specific types of DS- and DR-TB. For patients who do not fit these categories, the Joint Panel’s prior guidelines should be consulted (6, 7).
Drug-resistant TBrecommendation updates include the use of novel regimens containing bedaquiline, pretomanid, and linezolid with or without moxifloxacin. Conclusions: All-oral, shorter treatment regimens for TB are now recommended for use in eligible individuals.
Updated clinical practice guidelines have been released for the treatment of drug-susceptible and drug-resistant tuberculosis (TB) infection in children and adults.
The World Health Organization’s Global Programme on Tuberculosis & Lung Health (WHO/GTB) has integrated all existing recommendations into a single, unified set of consolidated tuberculosis (TB) guidelines. These guidelines are organized into modules, each tailored to specific programmatic areas.
A panel of experts from ATS, CDC, ERS, IDSA, and We Are TB authored the updates, incorporating clinical guidance resulting from the results of recent clinical treatment trials, including CDC's TB Clinical Trials Consortium.
The American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America jointly sponsored the development of this guideline for the treatment of drug-susceptible tuberculosis, which is also endorsed by the European Respiratory Society and the US National Tuberculosis Controllers Association.
The standard of care for initiating treatment of TB disease is 4-drug therapy. This initial 4-drug therapy is referred to as the intensive phase of treatment. Treatment with a single drug can lead to development of a bacterial population resistant to that drug.
This scoping review aims to provide a comprehensive overview of current practices in treating DS-TB and DR-TB in children and adults, focusing on recent updates in treatment strategies. This review includes studies published after 2022 to specifically capture the updates and advances in TBtreatment following the latest WHO guidelines.
The World Health Organization (WHO) today released its Consolidated guidelines on tuberculosis (TB)- Module 4: treatment and care, consolidating all previous guidelines into a single comprehensive document and introducing significant improvements in treatment options for people with multidrug-resistant or rifampicin-resistant tuberculosis (MDR ...
